Valion Bio Launches $15M Offering at $0.51/Unit, Deeply Dilutive for Micro-Cap
VBIO sits 20% above its 52-week low of $0.4.
Summary
Valion Bio is offering up to 29.4 million shares with accompanying warrants at $0.51 per unit, aiming to raise up to $15 million. The offering price is a modest premium to the current $0.48 stock price, but the share count is massive relative to the company's $2.1 million market cap — this is highly dilutive. The company is burning cash fast, with a going concern warning and a recent $6.2 million quarterly loss on near-zero revenue. This follows a series of desperate capital raises, including a $250,000 preferred stock deal in June and a pending reverse split proposal. The offering buys time but signals severe financial strain.
At the time of this announcement, VBIO was trading at $0.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $0.40 to $5.60. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.